Target intelligence / Profile preview

SH3 domain containing kinase binding protein 1 (SH3KBP1)

Target
SH3KBP1
Molecular classification
Adapter protein, Signal transduction modulator, Scaffold protein, Other
01

Overview

SH3 domain containing kinase binding protein 1 (SH3KBP1, also called CIN85) is an adapter/scaffold protein encoded by the human SH3KBP1 gene. It contains multiple Src homology 3 (SH3) domains, enabling it to mediate protein-protein interactions in diverse cellular processes. SH3KBP1 is essential for clathrin-dependent endocytosis, regulation of receptor tyrosine kinase pathways (like EGFR and MET), cytoskeletal rearrangement, cell adhesion, immune cell activation, and regulation of apoptotic signaling. It interacts with CBL and endophilins to promote receptor internalization, modulates TNF-alpha-induced apoptosis, and is implicated in cancer, immunodeficiency, and neurological disorders. No drugs directly target SH3KBP1, but its pathway involvement makes it a significant research target in oncology and immunology.

Other names
CIN85Cbl-interacting protein of 85 kDaCD2-binding protein 3 (CD2BP3)SH3 domain-containing kinase-binding protein 1Human Src family kinase-binding protein 1Src-related kinase binding protein-1HSB-1Ruk
02

Mechanism of action

Drugs targeting upstream or downstream pathways (e.g., EGFR inhibitors) may exert effects modulated by SH3KBP1, especially in receptor degradation or signal attenuation. No direct mechanisms for SH3KBP1-targeted drugs documented to date

03

Biological functions

Signal transductionApoptosisCell adhesionCytoskeletal organizationEndocytosis (especially clathrin-mediated)Immune responseRegulation of cell migrationLysosomal degradation of receptor tyrosine kinases
04

Disease associations

Cancer (modulation of growth factor receptor endocytosis, apoptosis, and cell migration)Immunodeficiency (e.g., Immunodeficiency 61)Autism spectrum disorderOther (potential role in infection and cellular stress response)
05

Safety considerations

No specific safety concerns documented because direct pharmacological targeting of SH3KBP1 is not established; hypothetical concerns could include immune dysregulation or interference with apoptosis if inhibitor were developed (speculative)
06

Interacting drugs

No well-established FDA-approved drugs known to directly target SH3KBP1 as of September 2025; pathways involving SH3KBP1 (such as EGFR, MET, TNF-alpha) are targeted by drugs, but not SH3KBP1 itself
07

Biomarkers

SH3KBP1 expression and activity have potential as research biomarkers in cancer and immune signaling contexts, but there are no clinical biomarkers formally approved for patient selection or monitoring

Beyond the preview

Go deeper on SH3 domain containing kinase binding protein 1 (SH3KBP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SH3 domain containing kinase binding protein 1 (SH3KBP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call